WO2005054848A3 - Diagnostics and therapeutics for diseases associated with g-protein-coupled inwardly rectifying potassium channel (girk2) - Google Patents

Diagnostics and therapeutics for diseases associated with g-protein-coupled inwardly rectifying potassium channel (girk2) Download PDF

Info

Publication number
WO2005054848A3
WO2005054848A3 PCT/EP2004/012824 EP2004012824W WO2005054848A3 WO 2005054848 A3 WO2005054848 A3 WO 2005054848A3 EP 2004012824 W EP2004012824 W EP 2004012824W WO 2005054848 A3 WO2005054848 A3 WO 2005054848A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
girk2
therapeutics
diagnostics
protein
Prior art date
Application number
PCT/EP2004/012824
Other languages
French (fr)
Other versions
WO2005054848A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005054848A2 publication Critical patent/WO2005054848A2/en
Publication of WO2005054848A3 publication Critical patent/WO2005054848A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The invention provides a human GIRK2 which is associated with the cardiovascular diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, neurological diseases, urological diseases and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, neurological diseases, urological diseases and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of GIRK2 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/012824 2003-11-25 2004-11-12 Diagnostics and therapeutics for diseases associated with g-protein-coupled inwardly rectifying potassium channel (girk2) WO2005054848A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03026923 2003-11-25
EP03026923.7 2003-11-25

Publications (2)

Publication Number Publication Date
WO2005054848A2 WO2005054848A2 (en) 2005-06-16
WO2005054848A3 true WO2005054848A3 (en) 2006-01-05

Family

ID=34639259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/012824 WO2005054848A2 (en) 2003-11-25 2004-11-12 Diagnostics and therapeutics for diseases associated with g-protein-coupled inwardly rectifying potassium channel (girk2)

Country Status (1)

Country Link
WO (1) WO2005054848A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007535959A (en) * 2004-05-10 2007-12-13 エボテツク・ニユーロサイエンシーズ・ゲー・エム・ベー・ハー Diagnostic and therapeutic use of KCNJ6 for Alzheimer's disease
US7749371B2 (en) 2005-09-30 2010-07-06 Lifescan, Inc. Method and apparatus for rapid electrochemical analysis
EP2380595A1 (en) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
EP3622958B1 (en) * 2017-05-09 2024-03-20 Zhejiang University Use of potassium ion channel inhibitor for treatment of depression and pharmaceutical composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744594A (en) * 1994-02-08 1998-04-28 Oregon Health Sciences University DNA encoding ATP-sensitive potassium channel genes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744594A (en) * 1994-02-08 1998-04-28 Oregon Health Sciences University DNA encoding ATP-sensitive potassium channel genes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLEDNOV Y A ET AL: "A pervasive mechanism for analgesia: Activation of GIRK2 channels.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. 1, 7 January 2003 (2003-01-07), pages 277 - 282, XP002328189, ISSN: 0027-8424 *
KOBAYASHI TORU ET AL: "Inhibition of G protein-activated inwardly rectifying K+ channels by fluoxetine (Prozac).", BRITISH JOURNAL OF PHARMACOLOGY, vol. 138, no. 6, March 2003 (2003-03-01), pages 1119 - 1128, XP002328188, ISSN: 0007-1188 *
MEEI-LING TSAUR ET AL: "ISOLATION OF A CDNA CLONE ENCODING A KATP CHANNEL-LIKE PROTEIN EXPRESSED IN INSULIN-SECRETING CELLS, LOCALIZATION OF THE HUMAN GENE TO CHROMOSOME BAND 21Q22.1, AND LINKAGE STUDIES WITH NIDDM", DIABETES, NEW YORK, NY, US, vol. 44, no. 5, 1 May 1995 (1995-05-01), pages 592 - 596, XP000611937, ISSN: 0012-1797 *
WICKENDEN ALAN D: "Potassium channels as anti-epileptic drug targets.", NEUROPHARMACOLOGY, vol. 43, no. 7, December 2002 (2002-12-01), pages 1055 - 1060, XP002328187, ISSN: 0028-3908 *

Also Published As

Publication number Publication date
WO2005054848A2 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2006010498A3 (en) Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005114207A3 (en) Diagnostics and therapeutics for diseases associated with aminopeptidase n (anpep)
WO2005054848A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled inwardly rectifying potassium channel (girk2)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2004097358A3 (en) Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2004071378A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2005050197A3 (en) Diagnostics and therapeutics for diseases associated with protein-coupled inwardly rectifying potassium channel girk4 (girk4)
WO2004099783A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2005040791A3 (en) Diagnostics and therapeutics for diseases associated with somatostatin- and angiogenin-like peptide receptor (salpr)
WO2005101006A3 (en) Diagnostics and therapeutics for diseases associated with retinoid x receptor beta (rxrb)
WO2005054863A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled inwardly rectifying potassium channel (girk 3)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2005054865A3 (en) Diagnostics and therapeutics for diseases associated with protein-coupled inwardly rectifying potassium channel (girk1)
WO2005052586A3 (en) Diagnostics and therapeutics for diseases associated with potassium channel, subfamily k, member 3 (kcnk3)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase